

# Kadiamada N R Chengappa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7711106/publications.pdf>

Version: 2024-02-01

55  
papers

2,228  
citations

218592

26  
h-index

214721

47  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2474  
citing authors

#	ARTICLE	IF	CITATIONS
1	Parting notesâ€™An editor's perspective. <i>Bipolar Disorders</i> , 2022, 24, 7-7.	1.1	1
2	Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatmentâ€™resistantÂschizophrenia. <i>Psychopharmacology</i> , 2022, 239, 2503-2514.	1.5	7
3	Group teletherapy for firstâ€™episode psychosis: Piloting its integration with coordinated specialty care during the COVIDâ€™19 pandemic. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2021, 94, 382-389.	1.3	22
4	ECT for a pregnant patient with bipolar disorder in the COVIDâ€™19 Era: A clinical conundrum. <i>Bipolar Disorders</i> , 2021, 23, 524-527.	1.1	3
5	Less is more: Deprescribing anticholinergic medications in persons with severe mental illness. , 2021, 33, E1-E13.		10
6	Deprescribing anticholinergic medication in the community mental health setting: A quality improvement initiative. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1841-1846.	1.5	5
7	From Office-Based Treatment to Telehealth: Comparing Clinical Outcomes and Patient Participation in a Psychiatric Intensive Outpatient Program with a Large Transdiagnostic Sample. <i>Telemedicine Journal and E-Health</i> , 2021, , .	1.6	3
8	Racial Differences in S100b Levels in Persons with Schizophrenia. <i>Psychiatric Quarterly</i> , 2020, 91, 137-145.	1.1	8
9	An Editorial Note â€™ . <i>Bipolar Disorders</i> , 2020, 22, 7-8.	1.1	0
10	Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic. <i>Schizophrenia Research</i> , 2020, 222, 499-500.	1.1	14
11	Bipolar disorders: Cornering debate. <i>Bipolar Disorders</i> , 2018, 20, 6-6.	1.1	0
12	Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 1334-1342.	2.8	17
13	Adjunctive Use of a Standardized Extract of &lt;em&gt;Withania somnifera&lt;/em&gt; (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	44
14	Have Your Say!. <i>Bipolar Disorders</i> , 2017, 19, 5-5.	1.1	1
15	Why â€™mood stabilizerâ€™™ needs stability: Polar views on its utility. <i>Bipolar Disorders</i> , 2017, 19, 414-416.	1.1	10
16	All aboard: the Journal's journey to broader contentâ€™ment. <i>Bipolar Disorders</i> , 2017, 19, 412-413.	1.1	1
17	Reducing Anticholinergic Medication Burden in Patients With Psychotic or Bipolar Disorders. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1270-e1275.	1.1	28
18	Journal expansion: Bipolar Big Bang to events on the horizon. <i>Bipolar Disorders</i> , 2016, 18, 629-630.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. <i>Nicotine and Tobacco Research</i> , 2015, 18, ntv085.	1.4	16
20	Dr Chengappa and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 625-626.	1.1	0
21	Varenicline for Smoking Cessation in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 765-772.	1.1	74
22	Randomized Placebo-Controlled Adjunctive Study of an Extract of <i>Withania somnifera</i> for Cognitive Dysfunction in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1076-1083.	1.1	89
23	A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. <i>Schizophrenia Research</i> , 2012, 142, 145-152.	1.1	69
24	Atypical mood stabilizers: a new role for neuroleptics?. <i>Bipolar Disorders</i> , 2011, 13, 583-586.	1.1	12
25	Hypomania: hype or mania?. <i>Bipolar Disorders</i> , 2010, 12, 758-763.	1.1	25
26	Long term outcomes in persons with bipolar disorder—Developing versus developed countries. <i>Asian Journal of Psychiatry</i> , 2010, 3, 49.	0.9	1
27	Subacute sclerosing panencephalitis presenting as schizophreniform disorder. <i>Acta Neuropsychiatrica</i> , 2009, 21, 45-47.	1.0	5
28	Lithium specificity in bipolar illness: a classic agent for the classic disorder. <i>Bipolar Disorders</i> , 2009, 11, 34-44.	1.1	98
29	Identifying and treating cognitive impairment in bipolar disorder. <i>Bipolar Disorders</i> , 2009, 11, 123-137.	1.1	145
30	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 193-194.	0.7	2
31	Changes in cigarette consumption in psychiatric patients: impact on side-effects or the efficacy of clozapine and olanzapine. <i>Acta Neuropsychiatrica</i> , 2008, 20, 324-326.	1.0	4
32	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. <i>Bipolar Disorders</i> , 2008, 10, 566-579.	1.1	40
33	A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. <i>Bipolar Disorders</i> , 2007, 9, 609-617.	1.1	29
34	Adjunctive Topiramate Therapy in Patients Receiving a Mood Stabilizer for Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1698-1706.	1.1	64
35	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. <i>Bipolar Disorders</i> , 2005, 7, 68-76.	1.1	43
36	The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. <i>Bipolar Disorders</i> , 2004, 6, 314-318.	1.1	115

#	ARTICLE	IF	CITATIONS
37	The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 57-63.	0.7	50
38	Leukopenia in clozapine treated patients may be induced by other drugs: a case series. <i>European Psychiatry</i> , 2004, 19, 506-509.	0.1	19
39	Dosage and Administration Issues of Antipsychotic Agents (and Adjunctive Medicines) in the Acute Stabilization of Psychoses. <i>CNS Spectrums</i> , 2004, 9, 6-10.	0.7	112
40	Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. <i>Bipolar Disorders</i> , 2003, 5, 1-5.	1.1	74
41	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. <i>Clinical Therapeutics</i> , 2003, 25, 530-541.	1.1	56
42	Relationship of Birth Cohort and Early Age at Onset of Illness in a Bipolar Disorder Case Registry. <i>American Journal of Psychiatry</i> , 2003, 160, 1636-1642.	4.0	121
43	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. <i>Clinical Therapeutics</i> , 2002, 24, 1576-1584.	1.1	108
44	Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. <i>European Psychiatry</i> , 2001, 16, 186-190.	0.1	78
45	Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 965-968.	0.9	32
46	Illness characteristics and their association with prescription patterns for bipolar I disorder. <i>Bipolar Disorders</i> , 2001, 3, 41-49.	1.1	29
47	The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. <i>Bipolar Disorders</i> , 2001, 3, 215-232.	1.1	72
48	Differentiating primary pathophysiologic from secondary adaptational processes. <i>Depression and Anxiety</i> , 2001, 14, 105-111.	2.0	6
49	The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. <i>Bipolar Disorders</i> , 2001, 3, 215-232.	1.1	3
50	Inositol as an add-on treatment for bipolar depression. <i>Bipolar Disorders</i> , 2000, 2, 47-55.	1.1	91
51	Psychotropic drug prescription patterns among patients with bipolar I disorder. <i>Bipolar Disorders</i> , 2000, 2, 120-130.	1.1	98
52	Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. <i>Bipolar Disorders</i> , 2000, 2, 191-195.	1.1	105
53	Response to placebo among bipolar I disorder patients experiencing their first manic episode. <i>Bipolar Disorders</i> , 2000, 2, 332-335.	1.1	7
54	Impact of Risperidone on Seclusion and Restraint at a State Psychiatric Hospital. <i>Canadian Journal of Psychiatry</i> , 2000, 45, 827-832.	0.9	26

#	ARTICLE	IF	CITATIONS
55	Topiramate as add-on treatment for patients with bipolar mania. <i>Bipolar Disorders</i> , 1999, 1, 42-53.	1.1	135